ERNA - CIK 0000748592
The table below shows Eterna Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $582.00K | $68.00K | $0.00 | - | $5.80M |
| Cost of revenue | - | $96.00K | $236.00K | $0.00 | - | - |
| Gross profit | - | $486.00K | -$168.00K | $0.00 | - | - |
| R&D | - | - | - | - | - | $2.00K |
| SG&A | $5.16M |
Eterna Therapeutics Inc. reported annual revenue of $582.00K for fiscal year 2024. That is up 755.9% from $68.00K in fiscal 2023. Over the 10 fiscal years shown, annual revenue declined from $26.05M (FY 2014) to $582.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $13.13M |
| $14.59M |
| $16.84M |
| $14.72M |
| $8.09M |
| Operating income | -$9.32M | -$15.67M | -$21.14M | -$33.22M | -$113.73M | -$7.25M |
| Income tax | -$45.00K | $30.00K | -$3.00K | $45.00K | $64.00K | $0.00 |
| Net income | -$14.08M | -$44.54M | -$21.67M | -$24.58M | -$122.55M | -$7.29M |
| EPS (diluted) | -$2.24 | -$48.96 | -$4.08 | -$8.06 | -$56.61 | -$0.41 |